Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.36M | 3.20M | 2.93M | 2.61M | 1.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.82M | 7.31M | 6.09M | 8.36M | 10.10M |
| Operating Income | -8.82M | -7.31M | -6.09M | -8.36M | -10.10M |
| Income Before Tax | -8.82M | -7.31M | -6.09M | -8.36M | -10.10M |
| Income Tax Expenses | 1.60K | 1.60K | -- | -- | -- |
| Earnings from Continuing Operations | -8.82 | -7.31 | -6.09 | -8.36 | -10.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.82M | -7.31M | -6.09M | -8.36M | -10.10M |
| EBIT | -8.82M | -7.31M | -6.09M | -8.36M | -10.10M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.24 | -1.93 | -6.42 | -14.54 | -30.84 |
| Normalized Basic EPS | -0.15 | -1.20 | -4.01 | -9.08 | -19.27 |
| EPS Diluted | -0.24 | -1.93 | -6.42 | -14.54 | -30.84 |
| Normalized Diluted EPS | -0.15 | -1.20 | -4.01 | -9.08 | -19.27 |
| Average Basic Shares Outstanding | 143.45M | 108.30M | 72.37M | 37.18M | 2.15M |
| Average Diluted Shares Outstanding | 143.45M | 108.30M | 72.37M | 37.18M | 2.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |